NovaBridge Biosciences SEC filings NBP
NovaBridge Biosciences has 330 filings in SEC EDGAR's recent list, going back to Jul 29, 2019. Its latest annual report, Form 20-F, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 28, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 17, 2026 | — |
| 424B3 | Prospectus | Oct 30, 2025 | — |
| S-8 | Employee stock plan registration | Sep 11, 2025 | — |
| 424B5 | Prospectus supplement | Aug 4, 2025 | — |
| F-6EF | Filing | Aug 1, 2025 | — |
| 424B5 | Prospectus supplement | Jul 11, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | May 2, 2025 | — |
| S-8 | Employee stock plan registration | May 30, 2024 | — |
| S-8 | Employee stock plan registration | Jun 17, 2022 | — |
| 424B3 | Prospectus | Mar 31, 2022 | — |
| 424B3 | Prospectus | Jan 14, 2022 | — |
| 424B3 | Prospectus | Nov 26, 2021 | — |
| 424B3 | Prospectus | Nov 12, 2021 | — |
| 424B3 | Prospectus | Jul 16, 2021 | — |
| 424B3 | Prospectus | Jun 23, 2021 | — |
| S-8 | Employee stock plan registration | May 28, 2021 | — |
| 424B3 | Prospectus | Apr 30, 2021 | — |
| 424B3 | Prospectus | Mar 19, 2021 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Mar 19, 2021 | — |
| 424B5 | Prospectus supplement | Feb 9, 2021 | — |
| 424B5 | Prospectus supplement | Feb 8, 2021 | — |
| 424B5 | Prospectus supplement | Feb 5, 2021 | — |
| F-3ASR | Filing | Feb 5, 2021 | — |
| 424B5 | Prospectus supplement | Feb 5, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Dec 1, 2020 | — |
| S-8 | Employee stock plan registration | Jul 15, 2020 | — |
| 424B4 | Prospectus | Jan 21, 2020 | — |
| F-1/A | Amendment no.3 to form f-1 | Jan 14, 2020 | — |
| F-1/A | Amendment no.2 to form f-1 | Jan 3, 2020 | — |
| F-6 | Filing | Dec 18, 2019 | — |
| F-1/A | Amendment no.1 to form f-1 | Nov 4, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Oct 29, 2019 | — |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1778016
- Former names
- I-Mab (until Oct 28, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.